AdaptHealth reported a challenging Q2 with a loss of $1.07 per share and a $106 million revenue shortfall, prompting a lowered profitability outlook. Despite these setbacks, its core Sleep Health and Respiratory Health segments grew strongly, with net revenue rising 12.7% to $740.3 million. UBS maintained a Buy rating but cut the price target from $14 to $10, reflecting confidence in long-term growth amid near-term difficulties. The company is focusing on its high-growth home medical equipment segments to drive future performance.
AdaptHealth sharply reduced its full-year 2026 adjusted EBITDA guidance from $680-$730 million to approximately $490-$520 million, causing its stock to fall by up to 26%. The company initially cited elevated labor costs normalizing, but later attribu...
AdaptHealth's shares dropped over 30% following a disappointing Q2 report, including a $1.07 loss per share and missing revenue by $106 million. The company is selling its low-margin diabetes business to Cardinal Health for $235 million to concentrat...
Stocks fell sharply due to various factors including a 58.71% drop in the Defiance Daily Target 2x Short PLTR ETF, driven by strong gains in Palantir Technologies, which the ETF inversely tracks. AdaptHealth shares dropped 38.09% amid a legal investi...
Holzer & Holzer, LLC announced an investigation into AdaptHealth Corp. following the company's revised financial guidance and second quarter 2026 results. AdaptHealth reported a decrease in cash flow from operations to $239 million year-to-date 2026,...
